Fertility and Sterility
Volume 93, Issue 7 , Pages 2303-2310 , 1 May 2010

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial

  • Daniela Romualdi, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Maddalena Giuliani, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Francesca Cristello, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Anna Maria Fulghesu, M.D.

      Affiliations

    • Division of Gynecology, Obstetrics, and Pathophysiology of Human Reproduction, Department of Surgery, Maternal-Fetal Medicine, and Imaging, University of Cagliari, Cagliari, Italy
    • ,
  • Luigi Selvaggi, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Antonio Lanzone, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • “Oasi” Institute for Research, Troina, Italy
    • ,
  • Maurizio Guido, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
    • Corresponding Author InformationReprint requests: Maurizio Guido, M.D., Ph.D., Department of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168 Rome, Italy (FAX: +39-06-3057794).

Received 1 October 2008 ,Revised 14 January 2009 ,Accepted 19 January 2009.

References 

  1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800
  3. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone–induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 1988;123:733–739
  4. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone–binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–89
  5. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–514
  6. Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, et al. Ultrasound in polycystic ovary syndrome—the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Hum Reprod. 2007;22:2501–2508
  7. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril. 2001;76:326–331
  8. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–146
  9. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004;81:355–360
  10. Palomba S, Falbo A, Orio F, Manguso F, Russo T, Tolino A, et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in nonobese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod. 2005;20:2879–2886
  11. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691–696
  12. Rotterdam ESHRE/ASRM–Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  13. Van Hooff MH, Voorhorst FJ, Koptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine feathures of polycystic ovary syndrome in a random population sample of 14–16 years old adolescents. Hum Reprod. 1999;14:2223–2229
  14. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab. 1983;57:320–326
  15. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48:167–172
  16. De Simone M, Verrotti A, Iughetti L, Palombo M, Farello G, Di Cesare E, et al. Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. J Endocrinol Invest. 2001;24:438–444
  17. Dietary Guidelines for Americans . Publication 261-495/20124. Washington, DC: U.S. Department of Agriculture; 1990;
  18. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447
  19. Orsini LF, Venturoli S, Lorusso R, Pluchinotta V, Paradisi R, Bovicelli L. Ultrasonic findings in polycystic ovarian disease. Fertil Steril. 1985;43:709–714
  20. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985;2:1375–1379
  21. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157:669–676
  22. Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:3128–3135
  23. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril. 2007;87:870–875
  24. Krstevska B, Ch Dimitrovski, Pemovska G, Misevska S, Dimova Z, Simeonova S, et al. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi. 2006;27:57–66
  25. Hermann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524–530
  26. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876–1880
  27. Velázquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997;90:392–395
  28. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48:511–519
  29. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73:1149–1154
  30. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab. 1997;82:556–560
  31. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R. Pabuçcu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. Eur J Obstet Gynecol Reprod Biol. 2005;123:204–211
  32. Kaleli S, Erel CT, Oral E, Elter K, Akman C, Colgar U. Ovarian stromal hypertrophy in polycystic ovary syndrome. J Reprod Med. 1998;43:893–897
  33. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf). 1994;41:557–562
  34. Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM, et al. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?. Hum Reprod. 2006;21:3108–3115
  35. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril. 2007;87:870–875
  36. Pache TD, de Jong FH, Hop WC, Fauser BC. Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. Fertil Steril. 1993;59:544–549
  37. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf). 1989;30:459–470
  38. el Tabbakh GH, Lotfy I, Azab I, Rahman HA, Southren AL, Aleem FA. Correlation of the ultrasonic appearance of the ovaries in polycystic ovarian disease and the clinical, hormonal, and laparoscopic findings. Am J Obstet Gynecol. 1986;154:892–895
  39. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633–667
  40. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril. 2001;76:517–524
  41. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human steroidogenesis. Fertil Steril. 2003;79:956–962
  42. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intraovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10:107–117
  43. Sonntag B, Götte M, Wülfing P, Schüring A, Kiesel L, Greb RR. Metformin alters insulin signalling and viability of human granulosa cells. Fertil Steril. 2005;84:1173–1179

 D.R. has nothing to disclose. M.G. has nothing to disclose. F.C. has nothing to disclose. A.M.F. has nothing to disclose. L.S. has nothing to disclose. A.L. has nothing to disclose. M.G. has nothing to disclose.

 Supported by a grant from the Ministry of Public Health for “La prevenzione dell'handicap mentale,” Istituto di Ricovero e Cura a Carattere Scientifico Troina and by a grant from the Ministry of Education, Univerities, and Research, 2005.

PII: S0015-0282(09)00239-8

doi: 10.1016/j.fertnstert.2009.01.114

Fertility and Sterility
Volume 93, Issue 7 , Pages 2303-2310 , 1 May 2010

Article Tools

* Image Usage & Resolution